Henry T. Lynch, the father of hereditary cancer detection and prevention, died June 2. He was 91.
FDA has approved a tumor-treating fields device in combination with pemetrexed plus platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced, or metastatic malignant pleural mesothelioma.
FDA has approved Piqray (alpelisib, formerly BYL719) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human epidermal growth factor receptor-2 negative, PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test following progression on or after an endocrine-based regimen.
FDA approved lenalidomide (Revlimid) in combination with a rituximab product for previously treated follicular lymphoma and previously treated marginal zone lymphoma.
FDA approved the addition of overall survival data in labeling for gilteritinib (Xospata), which is indicated for adult patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation as detected by an FDA-approved test.
Early-onset colorectal cancer is rising most rapidly in Western states, where healthy behaviors are prominent, according to a new study from the American Cancer Society and Ohio State University. The authors of the study, which appears in JNCI, say the findings indicate the need for further etiologic studies to explore early-life colorectal carcinogenesis.
Researchers at the Johns Hopkins Kimmel Cancer Center have developed a blood test that can detect the presence of seven different types of cancer by spotting unique patterns in the fragmentation of DNA shed from cancer cells and circulating in the bloodstream.
Project ECHO, a service that provides physicians in rural areas with access to multidisciplinary expertise, will soon announce partnerships with four cancer centers—Dana-Farber Cancer Institute, Mayo Clinic Cancer Center, University of New Mexico Comprehensive Cancer Center, and Yale Cancer Center.
A public health initiative aimed at preventing cervical cancer in at-risk Appalachian families from Ohio, Kentucky, Virginia, and West Virginia is underway with support from an $11 million NCI grant to Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
The American Cancer Society has been awarded a $1.99 million, five-year grant to improve support and access to care for people living with cancer in low-and-middle-income countries, particularly sub-Saharan Africa. This funding will help ACS expand patient navigation to countries with a growing burden of cancer.
